- - oalib

OALib Journal期刊
ISSN: 2333-9721
费用：99美元

投递稿件

为什么选择我们？ >>

- 开源期刊

- 同行审议

- 快速出刊

- 终身存储

- 免费检索

- 免费推广

- 更多...

- 搜索引擎

-

ISSN Print: 1532-1827

ISSN Online:

主页: https://www.nature.com/bjc

分享:

Harnessing the innate immune system and local immunological microenvironment to treat colorectal cancer

Reduction of cervical cancer incidence within a primary HPV screening pilot project (WOLPHSCREEN) in Wolfsburg, Germany

Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial

Coffee consumption by type and risk of digestive cancer: a large prospective cohort study

Lipid metabolism in cancer cells under metabolic stress

A NOTCH added to metabolomics

Moving from one to many: insights from the growing list of pleiotropic cancer risk genes

A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer

Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08)

Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma

Targeting β-catenin overcomes MEK inhibition resistance in colon cancer with KRAS and PIK3CA mutations

Ingested asbestos in filtered beer, in addition to occupational exposure, as a causative factor in oesophageal adenocarcinoma

A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment

Increased expression of the immunosuppressive interleukin-35 in patients with non-small cell lung cancer

Predictive value of inflammatory markers for cancer diagnosis in primary care: a prospective cohort study using electronic health records

Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes

Metabolic reprogramming and Notch activity distinguish between non-small cell lung cancer subtypes

A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours

How rapid advances in imaging are defining the future of precision radiation oncology

A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial

The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution

A systematic review and quality assessment of individualised breast cancer risk prediction models

CE–MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer

Family history of cancer and risk of paediatric and young adult’s testicular cancer: A Norwegian cohort study

Low tumour PPM1H indicates poor prognosis in colorectal cancer via activation of cancer-associated fibroblasts

Understanding the impact of socioeconomic differences in colorectal cancer survival: potential gain in life-years

Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study

Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features

Risk of cardiovascular events in men treated for prostate cancer compared with prostate cancer-free men

A key genomic subtype associated with lymphovascular invasion in invasive breast cancer

The impact of immediate breast reconstruction on the time to delivery of adjuvant therapy: the iBRA-2 study

Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial

Poor outcome in hypoxic endometrial carcinoma is related to vascular density

Cell lines and immune classification of glioblastoma define patient’s prognosis

Physical activity during adolescence and risk of colorectal adenoma later in life: results from the Nurses’ Health Study II

Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study

The anaphase-promoting complex/cyclosome: a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma

International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation

A novel NPM1-RARG-NPM1 chimeric fusion in acute myeloid leukaemia resembling acute promyelocytic leukaemia but resistant to all-trans retinoic acid and arsenic trioxide

Prediabetes and diabetes in relation to risk of gastric adenocarcinoma

Case–control study of paternal occupational exposures and childhood lymphoma in Great Britain, 1962–2010

LGR5 expression predicts peritoneal recurrence after curative resection of primary colon cancer

ECT2 associated to PRICKLE1 are poor-prognosis markers in triple-negative breast cancer

Teaching an old dog new tricks: next-generation CAR T cells

Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint

A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours

Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit

(Pro)renin receptor promotes colorectal cancer through the Wnt/beta-catenin signalling pathway despite constitutive pathway component mutations

Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype

Whole-colon investigation vs. flexible sigmoidoscopy for suspected colorectal cancer based on presenting symptoms and signs: a multicentre cohort study

©2008-2020 OALib, Inc | Public user content licensed CC-BY 4.0 unless otherwise specified. OALib ISSN Online: 2333-9721 OALib ISSN Print: 2333-9705